NASDAQ: LXRXLexicon Pharmaceuticals Inc Stock Ownership - Who owns Lexicon Pharmaceuticals?
Insider buying vs selling
Have Lexicon Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Wendy McDermott | SVP Human Resources | 2026-02-28 | 68,107 | $1.47 | $100.12kSell |
| Scott M. Coiante | SVP Chief Financial Officer | 2026-02-28 | 54,881 | $1.47 | $80.68kSell |
| Brian T. Crum | SVP General Counsel Secr. | 2026-02-28 | 105,019 | $1.47 | $154.38kSell |
| Lisa Defrancesco | SVP IR and Corp Comm | 2026-02-28 | 74,572 | $1.47 | $109.62kSell |
| Michael Exton | Chief Executive Officer | 2026-02-28 | 204,831 | $1.47 | $301.10kSell |
| Suma Gopinathan | SVP Discovery | 2026-02-28 | 24,338 | $1.47 | $35.78kSell |
| Craig B. Granowitz | SVP Chief Medical Officer | 2026-02-28 | 109,098 | $1.47 | $160.37kSell |
| Rachel Yap Martens | SVP Partnerships Corp Strat | 2026-02-28 | 35,826 | $1.47 | $52.66kSell |
| Raymond Debbane | Director | 2026-02-25 | 2,000 | $1.49 | $2.98kBuy |
| Raymond Debbane | Director | 2026-02-23 | 100,000 | $1.47 | $147.00kBuy |
LXRX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when LXRX insiders and whales buy or sell their stock.
LXRX Shareholders
What type of owners hold Lexicon Pharmaceuticals Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Raymond Debbane | 85.09% | 360,496,783 | $587.61M | Insider |
| International Sca Artal | 75.19% | 318,557,433 | $519.25M | Insider |
| Participations Sa Rl Artal | 32.24% | 136,588,915 | $222.64M | Insider |
| Artal Group Sa | 32.14% | 136,180,481 | $221.97M | Institution |
| Siren LLC | 9.19% | 38,918,903 | $63.44M | Institution |
| Fmr LLC | 8.93% | 37,834,207 | $61.67M | Institution |
| Amaury Wittouck | 8.36% | 35,402,689 | $57.71M | Insider |
| Siren LLC | 8.36% | 35,402,689 | $57.71M | Insider |
| Invus Public Equities LP | 8.36% | 35,402,689 | $57.71M | Insider |
| Cv Invus | 7.14% | 30,248,505 | $49.31M | Insider |
LXRX vs Biotech Stocks
Lexicon Pharmaceuticals Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.